archive-com.com » COM » E » ENDEAVOURVISION.COM

Total: 462

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • New Data Demonstrate Simple Insulin Delivery Device Can Significantly Reduce Barriers to Insulin Treatment Among People with Type 2 Diabetes
    a strong and clinically significant effect of PaQ on the mean BIT total score Patients perceived less hardship from insulin therapy less stigmatization by insulin injection and less fear of hypoglycemia Diabetes related distress was also slightly reduced The reduction in perceived hardship of insulin treatment and feeling of stigmatization might be at least partly explained by the fact that PaQ use replaced on average 5 2 daily insulin injections said Dr Mader That equates to a meaningful reduction in the amount of time as well as inconvenience and discomfort associated with insulin injections for these patients Data on PaQ feasibility of use efficacy and safety were previously presented at the 6th International Conference on Advanced Technologies Treatments for Diabetes ATTD in Paris France These data demonstrated that in the Graz study PaQ safely and effectively delivered patients insulin requirements with a high level of patient satisfaction and acceptance No severe hypoglycemic events occurred during the study baseline period or while participants were on PaQ and all patients were able to correctly assemble and use PaQ with just one hour of training The Need for Simple Insulin Infusion There are currently more than 11 million people in the United States and European Union who are taking insulin injections to manage their type 2 diabetes Studies suggest that simple continuous subcutaneous insulin infusion CSII regimens may improve glycemic control and quality of life among these individuals However current CSII has not been widely used in T2D to date due to its complexity and cost We have been extremely gratified by the ability of simple insulin therapy to free people with type 2 diabetes from the burden of multiple daily injections so that they can maintain target glycemic values and potentially improve their long term health said James Peterson founder and CEO CeQur About PaQ PaQ is a discreet wearable device that provides three days of consistent basal insulin delivery along with easy on demand bolus insulin The small device comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor About CeQur SA CeQur is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease The company is headquartered in Horw Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 The company s lead product candidate is the PaQ Insulin Delivery Device a novel wearable device that provides freedom from multiple daily injections More information can be found at www cequrcorp com Notes Hoerger T et al Is Glycemic Control Improving in U S Adults Diabetes Care 2008 31 81 86 Mohammed AK et al Characteristics Associated with Poor Glycemic Control Among Adults with Self Reported Diagnosed Diabetes National Health and Nutrition Examination Survey United States 2007 2010 Mor Mort Weekly Rprt 2012 61 32 37 Peyrot M Rubin RR Kruger DF Travis LB Correlates of insulin injection omission Diabetes Care 2010 33

    Original URL path: http://www.endeavourvision.com/news-n188-c67-New+Data+Demonstrate+Simple+Insulin+Deli.htm (2016-04-25)
    Open archived version from archive


  • CeQur Announces Positive Results from Study Evaluating Simple Insulin Delivery Device Among People with Type 2 Diabetes
    injections required to control their blood sugar Study endpoints included glycemic control patient satisfaction and safety The study was led by Professor Thomas Pieber head of the Division of Endocrinology and Metabolism at the University Hospital in Graz Austria Data presented for the first time today demonstrate that PaQ safely and effectively delivered patients insulin requirements with a high level of patient satisfaction and acceptance No severe hypoglycemic events occurred during the study baseline period or while participants were on PaQ All patients were able to correctly assemble and use PaQ with just one hour of training PaQ was logically designed to address common specific treatment challenges faced by people with type 2 diabetes said Professor Pieber This study provides encouraging initial evidence that simple devices such as PaQ may help us reduce the incidence and impact of poor glycemic control among these individuals The Need for Simple Insulin Infusion There are currently more than 11 million people in the United States and European Union who are taking insulin injections to manage their type 2 diabetes Studies suggest that simple continuous subcutaneous insulin infusion CSII regimens may improve glycemic control and quality of life among these individuals However current CSII has not been widely used in T2D to date due to its complexity and cost Our mission is to provide people with type 2 diabetes a simple insulin therapy that can free them from the burden of multiple daily injections so that they can more comfortably and consistently maintain target glycemic values said James Peterson founder and CEO CeQur We re extremely pleased that this study provides evidence that PaQ can provide this freedom About CeQur SA CeQur is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease The company is headquartered in Horw Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 The company s lead product candidate is the PaQ Insulin Delivery Device a novel wearable device that provides freedom from multiple daily injections More information can be found at www cequrcorp com Contact Michele Parisi for CeQur 1 925 429 1850 mparisi biocommnetwork com 1 Hoerger T et al Is Glycemic Control Improving in U S Adults Diabetes Care 2008 31 81 86 2 Mohammed AK et al Characteristics Associated with Poor Glycemic Control Among Adults with Self Reported Diagnosed Diabetes National Health and Nutrition Examination Survey United States 2007 2010 Mor Mort Weekly Rprt 2012 61 32 37 3 Peyrot M Rubin RR Kruger DF Travis LB Correlates of insulin injection omission Diabetes Care 2010 33 240 5 back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and

    Original URL path: http://www.endeavourvision.com/news-n178-c67-CeQur+Announces+Positive+Results+from+St.htm (2016-04-25)
    Open archived version from archive

  • CeQur Receives CE Mark for PaQ® Insulin Delivery Device
    long term type 2 diabetes complications Studies indicate that simple continuous insulin infusion regimens may improve glycemic control and quality of life among individuals with type 2 diabetes CeQur recently announced the successful completion of a clinical study conducted with the University Hospital Graz Austria evaluating the ability of PaQ to replace insulin injections among people with type 2 diabetes Study endpoints included glycemic control patient satisfaction and safety CeQur expects to share initial results early next year About CeQur SA CeQur is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease The company is headquartered in Horw Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 The company s lead product candidate is the PaQ Insulin Delivery Device a novel wearable device that provides freedom from multiple daily injections More information can be found at www cequrcorp com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team

    Original URL path: http://www.endeavourvision.com/news-n173-c67-CeQur+Receives+CE+Mark+for+PaQ%AE+Insuli.htm (2016-04-25)
    Open archived version from archive

  • CeQur Completes Study Evaluating Ability of Simple Insulin Delivery Device to Replace Insulin Injections Among People with Type 2 Diabetes
    who struggle with the challenges of multiple daily insulin injections said Jay Warner senior vice president Clinical Development and Commercialization There are currently more than 11 million people in the United States and European Union who are taking insulin injections to manage their type 2 diabetes According to a recent publication half of all patients requiring multiple daily injections of insulin intentionally skip doses because they consider the injections embarrassing inconvenient painful and or disruptive to their daily activities Adhering to prescribed insulin therapy regimens is important because tight glucose control is vital to reducing the risk of long term type 2 diabetes complications Studies indicate that simple continuous insulin infusion regimens may improve glycemic control and quality of life among individuals with type 2 diabetes Companies have been rewarded for developing effective solutions for people with diabetes said James Peterson founder and CEO CeQur There is still a tremendous need for simple discrete effective and less invasive insulin therapy for people with type 2 diabetes We are excited to have completed this study because we feel confident that PaQ will deliver on its potential to help address this need About CeQur SA CeQur is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease The company is headquartered in Horw Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 The company s lead product candidate is the PaQ Insulin Delivery Device a novel wearable device that provides freedom from multiple daily injections More information can be found at www cequrcorp com Peyrot M Rubin RR Kruger DF Travis LB Correlates of insulin injection omission Diabetes Care 2010 33 240 5 Edelman SV Bode BW Bailey TS et al Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen Diabetes Technol Ther 2010 12 627 33 Contact Michele Parisi for CeQur 1 925 429 1850 mparisi biocommnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This

    Original URL path: http://www.endeavourvision.com/news-n168-c67-CeQur+Completes+Study+Evaluating+Ability.htm (2016-04-25)
    Open archived version from archive

  • Clinical Study begins on Insulin Delivery Device for Type 2s
    the United States take insulin to manage their disease When multiple daily injections are required however half of all patients skip doses citing inconvenience embarrassment pain and disruption of their daily routine CeQur s hope is that a discreet continuous insulin infusion will increase the percentage of type 2s who adhere to an insulin regimen More information about the device is available at www cequrcorp com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr Georges Karam co Founder President CEO Sequans With Endeavour Vision we have been able to establish at fast speed the personal trust level needed and also come to terms very quick They are highly professional partners and support us in every possible manner Christian Lindner Co Founder and CEO Retailo AG We wanted a Venture Capital investor who was prepared to share our vision to

    Original URL path: http://www.endeavourvision.com/news-n154-c67-Clinical+Study+begins+on+Insulin+Deliver.htm (2016-04-25)
    Open archived version from archive

  • CeQur SA names Robert O'Holla EVP for Regulatory Affairs
    our CeQur Insulin Infuser We re excited that we will have this best in class regulatory expert to lead the way to approval of what we think will be a best in class insulin infusion device CeQur is developing the CeQur Insulin Infuser a discreet wearable device that provides three days of consistent basal insulin delivery along with on demand bolus insulin at the push of a button The small device comprises a disposable infuser reservoir attached to a reusable electronic monitor O Holla s appointment provides additional depth to CeQur s management and executive team which comprises some of the most experienced and recognized experts in the development and commercialization of diabetes treatments and medical devices After working with Bob for 33 years at J J I can say without question that he is among the best in the business at building and implementing regulatory submission and GMP compliance strategies said Eric Milledge chairman of CeQur Milledge joined CeQur in October 2009 after 34 years at Johnson Johnson where he led the diabetes diagnostics and device units I am very happy to be working with Bob again to make the CeQur Insulin Infuser available to type 2 diabetes patients who need help managing their disease The simplicity convenience and discreteness of the CeQur Insulin Infuser will be important to a range of type 2 diabetes patients who are frustrated by the challenges associated with multiple daily insulin injections and the limitations of current insulin injection devices O Holla said I am eager to play my part in bringing this important advancement in insulin therapy to the many Geneva01 patients looking for ways to achieve better glucose control About CeQur SA CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease The company is headquartered in Montreux Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 as a spin out from Danfoss A S a large global Danish industrial products group The company s lead product candidate is the CeQur Insulin Infuser a novel wearable insulin delivery device that provides freedom from multiple daily injections by offering up to three days of consistent basal insulin delivery along with bolus insulin at the push of a button More information can be found at www cequrcorp com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert

    Original URL path: http://www.endeavourvision.com/news-n140-c67-CeQur+SA+names+Robert+O%27Holla+EVP+for+.htm (2016-04-25)
    Open archived version from archive

  • CeQur SA Appoints Eric Milledge Chairman of the Board of Directors
    retired from Johnson and Johnson in March 2006 Eric brings to CeQur a demonstrated ability to lead the successful development and commercialization of medical devices that improve quality of life for people with diabetes said Jim Peterson vice chairman and CEO CeQur We are extremely pleased to have the benefit of his vast experience to help guide our company CeQur is developing the CeQur Insulin Infuser a discreet wearable device that provides three days of consistent basal insulin delivery along with on demand bolus insulin at the push of a button The small device comprises a disposable infuser reservoir attached to a reusable electronic monitor The CeQur Insulin Infuser is a simple alternative that will offer people with type 2 diabetes freedom from multiple daily insulin injections said Milledge As people living with the disease know maintaining glycemic control and managing multiple daily insulin injections is a continuous challenge I m pleased to be part of CeQur s mission to make it easier for people with type 2 diabetes to stay in control of their disease About CeQur SA CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease The company is headquartered in Montreux Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 as a spin out from Danfoss A S a large global Danish industrial products group The company s lead product candidate is the CeQur Insulin Infuser a novel wearable insulin delivery device that provides freedom from multiple daily injections by offering up to three days of consistent basal insulin delivery along with bolus insulin at the push of a button More information can be found at www cequrcorp com Press contact Michele Parisi 1 925 429 1850 mparisi biocommnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are team players Those who understand your business and embrace your vision Those who know how to challenge your execution and to bring value This is why I recommend Endeavour Vision team to entrepreneurs looking for funding Dr Georges Karam co Founder President CEO Sequans With Endeavour Vision we have been able to establish at

    Original URL path: http://www.endeavourvision.com/news-n72-c67-CeQur+SA+Appoints+Eric+Milledge+Chairman.htm (2016-04-25)
    Open archived version from archive

  • CeQur SA Completes Series A Investment with 10 Million Dollar Raise in December 2009
    to obtain glycemic control said Eric Milledge chairman of the board CeQur Many of these individuals experience challenges as a result of having to administer multiple daily insulin injections The CeQur Insulin Infuser is a simple alternative that will offer people with type 2 diabetes freedom from these challenges and help them achieve their glycemic goals About CeQur SA CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease The company is headquartered in Montreux Switzerland with operations in Nordborg Denmark and Marlborough Massachusetts CeQur was established in January 2008 as a spin out from Danfoss A S a large global Danish industrial products group The company s lead product candidate is the CeQur Insulin Infuser a novel wearable insulin delivery device that provides freedom from multiple daily injections by offering up to three days of consistent basal insulin delivery along with bolus insulin at the push of a button More information can be found at www cequrcorp com Contact Michele Parisi for CeQur 1 925 429 1850 mparisi biocommnetwork com back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about

    Original URL path: http://www.endeavourvision.com/news-n78-c67-CeQur+SA+Completes+Series+A+Investment+w.htm (2016-04-25)
    Open archived version from archive



  •